

Allosteric effects of chromophore interaction with dimeric near-infrared fluorescent proteins engineered from bacterial phytochromes

Olesya V. Stepanenko, Mikhail Baloban, Grigory S. Bublikov, Daria M. Shcherbakova, Olga V. Stepanenko, Konstantin K. Turoverov, Irina M. Kuznetsova and Vladislav V. Verkhusha

Supplementary Information

Supplementary Figures

Supplementary Figure 1. Alignment of amino acid sequences of iRFP670, iRFP682 and iRFP713 with their wild-type templates *RpBphP6-PAS-GAF* and *RpBphP2-PAS-GAF*.

Supplementary Figure 2. SDS-PAGE gel with Coomassie Blue (CB) and ZnCl₂ (Zn) staining of the purified iRFP670, iRFP682, iRFP713 and their mutants.

Supplementary Figure 3. Gel filtration of iRFP670, iRFP682 and iRFP713/V256C.

Supplementary Figure 4. Spectral properties of iRFP713, iRFP682, iRFP670 and their mutants.

Supplementary Figure 5. Proposed BV adducts in the iRFP variants having either Cys15 in PAS domain or/and Cys256 in GAF domain.

Supplementary Figure 6. Changes in absorption of iRFP713 variants in GdnHCl.

Supplementary Figure 7. Stability of iRFP670, iRFP682 and iRFP713 variants in GdnHCl.


Supplementary Figure 8. Brightness of iRFP670, iRFP682 and their mutants in mammalian cells.

Supplementary Tables


Supplementary Table 1. Midpoints of GdnHCl-induced denaturation of iRFP670, iRFP682, iRFP713 and their variants with different location of Cys residues.

	1	10	20	30	40	50	60
<i>RpBphP2</i> (4E04)	MTEG S VARQP	DLST C DDEPI	HIPGAIQPHG	LLLALAADMT	IV-AGSDNLP	ELTGLAIGAL	
<i>RpBphP2</i>	MTEG S VARQP	DLST C DDEPI	HIPGAIQPHG	LLLALAADMT	IV-AGSDNLP	ELTGLAIGAL	
<i>iRFP713</i>	MAEG S VARQP	DL L T C DDEPI	HIPGAIQPHG	LLLALAADMT	IV-AGSDNLP	ELTGLAIGAL	
<i>iRFP682</i>	MAEG S VARQP	DL L T C DDEPI	HIPGAIQPHG	LLLALAADMT	IV-AGSDNLP	ELTGLAIGAL	
<i>RpBphP6</i>	MPRK-----V	DL T S C DREPI	HIPGSIQPCG	CLLACDAQAV	RITRITENAG	AFFGRETPRV	
<i>iRFP670</i>	MARK-----V	DL T S C DREPI	HIPGSIQPCG	CLLACDAQAV	RITRITENAG	AFFGRETPRV	
				PAS			
	70	80	90	100	110	120	
<i>RpBphP2</i> (4E04)	IGRSAADVFD	SETHNRLTIA	LAEPGAAVGA	PIAVGFTMPD	GERAFNGSWH	RHDQLVFLEL	
<i>RpBphP2</i>	IGRSAADVFD	SETHNRLTIA	LAEPGAAVGA	PIAVGFTMRK	DAGFV-GSWH	RHDQLVFLEL	
<i>iRFP713</i>	IGRSAADVFD	SETHNRLTIA	LAEPGAAVGA	PITVGFTMRK	DAGFI-GSWH	RHDQLIFLEL	
<i>iRFP682</i>	IGRSAADVFD	SETHNRLTIA	LAEPGAAVGA	PITVGFTMRK	DAGFI-GSWH	RHDQLIFLEL	
<i>RpBphP6</i>	GELLADYFGE	TEAHALRNAL	AQSSDPKRPA	LIFGWRDGLT	GRTFD-ISLH	RHDGTSIVEF	
<i>iRFP670</i>	GELLADYFGE	TEAHALRNAL	AQSSDPKRPA	LIFGWRDGLT	GRTFD-ISLH	RHDGTSIIEF	
				PAS			
	130	140	150	160	170	180	
<i>RpBphP2</i> (4E04)	EPPQRDVRY P	QAFFRSV R SA	IRRLQAA E TL	ESACAAA Q EQ	VREITGFDRV	MIYRFAS D FS	
<i>RpBphP2</i>	EPPQRDV A EP	QAFFR R TNSA	IRRLQAA E TL	ESACAAA Q EQ	VREITGFDRV	MIYRFAS D FS	
<i>iRFP713</i>	EPPQRDV A EP	QAFFR R TNSA	IRRLQAA E TL	ESACAAA Q EQ	VRKITGFDRV	MIYRFAS D FS	
<i>iRFP682</i>	EPPQRDV A EP	QAFFR R TNSA	IRRLQAA E TL	ESACAAA Q EQ	VRKITGFDRV	MIYRFAS D FS	
<i>RpBphP6</i>	EPAA A DQADN	PL-- R L T RQI	IARTK E LKSL	EEMA A R V PRY	LQ A MLG Y HRV	MMYRF A DDGS	
<i>iRFP670</i>	EPAA A EQADN	PL-- R L T RQI	IARTK E LKSL	EEMA A R V PRY	LQ A MLG Y HRV	MLYRF A DDGS	
		PAS		GAF			
	190	200	210	220	230	240	
<i>RpBphP2</i> (4E04)	GEVIAED R CA	EVE S YL G L H F	PASDIP A Q A R	RLYTIN P VRI	IPDIN Y R P VP	VTPDLN P RTG	
<i>RpBphP2</i>	GEVIAED R CA	EVE S YL G L H F	PASDIP A Q A R	RLYTIN P VRI	IPDIN Y R P VP	VTPDLN P V T G	
<i>iRFP713</i>	GEVIAED R CA	EVE S KL G L H Y	PASTV P A Q A R	RLYTIN P VRI	IPDIN Y R P VP	VTPDLN P V T G	
<i>iRFP682</i>	GVVIAED R CA	EVE S KL G L H Y	PASAV P A Q A R	RLYTIN P VRI	IPDIN Y R P VP	VTPDLN P V T G	
<i>RpBphP6</i>	GKVIG E AKRS	DLES F L G Q H F	PASDIP Q Q A R	LLYL K NAIRV	ISDSR G ISSR	IVPERD A S-G	
<i>iRFP670</i>	GMVIG E AKRS	DLES F L G Q H F	PASL V P Q Q A R	LLYL K NAIRV	VSDSR G ISSR	IVPE H D A S-G	
			GAF				
	250	260	270	280	290	300	
<i>RpBphP2</i> (4E04)	RPIDLS F AIL	RSVSP V H L EY	MRNIG M H G T M	SISIL R GERL	WGLI A CH H RK	PNYVD L EV R Q	
<i>RpBphP2</i>	RPIDLS F AIL	RSVSP V H L EY	MRNIG M H G T M	SISIL R GERL	WGLI A CH H RK	PNYVD L D G RQ	
<i>iRFP713</i>	RPIDLS F AIL	RSVSP V H L EY	MRNIG M H G T M	SISIL R GERL	WGLI V CH H RT	PYYVD L D G RQ	
<i>iRFP682</i>	RPIDLS F AIL	RSVSP C H L EY	MRNIG M H G T M	SISIL R GERL	WGLI V CH H RT	PYYVD L D G RQ	
<i>RpBphP6</i>	AALDLS F AHL	RSVSP I H L EY	LRN M GV S AS M	SLSII I D G T L	WGLI A CH H Y E	PRA V P M A Q R V	
<i>iRFP670</i>	AALDLS F AHL	RSIS P C H L E F	LRN M GV S AS M	SLSII I D G T L	WGLI A CH H Y E	PRA V P M A Q R V	
			GAF				
	310	320					
<i>RpBphP2</i> (4E04)	ACELVA Q V L A	WQIG V M E E Q A					
<i>RpBphP2</i>	ACELVA Q V L A	WQIG V M E E					
<i>iRFP713</i>	ACELVA Q V L A	WQIG V M E E					
<i>iRFP682</i>	ACELVA Q V L A	WQIG V M E E					
<i>RpBphP6</i>	AAEM F AD F FS	LH F T A A H H Q R					
<i>iRFP670</i>	AAEM F AD F LS	LH F T A A H H Q R					
			GAF				


Supplementary Figure 1. Alignment of amino acid sequences of iRFP670, iRFP682 and iRFP713 with their wild-type templates *RpBphP6*-PAS-GAF and *RpBphP2*-PAS-GAF. The residues in red font are the conservative Cys residue (Cys15) in the PAS domain of all BphPs and the unique Cys residue (Cys256) in the GAF domain of iRFP670 and iRFP682.




Supplementary Figure 2. SDS-PAGE gel with Coomassie Blue (CB) and ZnCl₂ (Zn) staining of the purified iRFP670, iRFP682, iRFP713 and their mutants. The Zn staining indicates the covalent binding of BV to all protein variants except those without Cys residues in both PAS and GAF domains.




Supplementary Figure 3. Gel filtration of iRFP670, iRFP682 and iRFP713/V256C. The protein concentrations were 0.5 mg/ml. The iRFP682 (solid blue line) and iRFP713/V256C (solid red line) proteins were eluted as the single peaks corresponding to the protein dimers. At this protein concentration and gel filtration conditions (see Methods) iRFP670 (solid green line) had the elution profile corresponding to the monomer, in contrast to its dimeric behavior previously observed in cells (Shcherbakova and Verkhusha, 2013). The dimer of iRFP713 (dashed black line) and the protein chromatography standards (solid grey lines) were used to evaluate the molecular weight.




Supplementary Figure 4. Spectral properties of iRFP713, iRFP682, iRFP670 and their mutants. Absorption and fluorescence spectra of (a) iRFP713, (b) iRFP682 and (c) iRFP670 variants with Cys residues either in PAS or in GAF domains, with or without both conservative Cys residues.




Supplementary Figure 5. Proposed BV adducts in the iRFP variants having either Cys15 in PAS domain or/and Cys256 in GAF domain. (a) Cys15 in PAS domain and Cys256 in GAF domain are mapped on the X-ray structure of RpBphP2-PAS-GAF protein (4E04 file in PDB). Cys residues are shown in yellow, and protein monomers in the dimer are marked in blue and gray. When free BV molecule with two double bonds in the pyrrole ring A covalently binds to Cys256 in the GAF domain, the spectral blue shift is observed with respect (b) to unbound BV and (c) to BV covalently bound to Cys15 in the PAS domain. (d, e) The blue spectral shift can result from the reduced length of the conjugated π -electron system due to BV-chromophore isomerization that leads to uncoupling of one double bond in the BV adducts from the rest of the conjugated electron system.



Supplementary Figure 6. Changes in absorption of iRFP713 variants in GdnHCl. The absorption spectra (left panels) and dependences of absorbance at 640 and 690 nm, or at 600, 660 and 690 nm (right panels) on GdnHCl concentration of **(a)** iRFP713/T204A and **(b)** iRFP713/C15S/V256C/T204A mutants are shown. The numbers on the curves indicate the denaturant concentration in the protein samples. Colored vertical dashed lines show the selected for further analysis wavelengths. The data were normalized to the absorption at corresponding wavelength of the iRFP713 variant in buffered solution ($n=3$; error bars are s.e.m.). The stability of the protein structure against GdnHCl-induced unfolding is shown as the dependences of the part of native molecules F_N on GdnHCl concentration (gray symbols). F_N was calculated on the basis of ellipticity at 222 nm.



Supplementary Figure 7. Stability of iRFP670, iRFP682 and iRFP713 variants in GdnHCl. Stability of (a) iRFP670, (b) iRFP682 and (c) iRFP713 variants with Cys in GAF or PAS domains, without or with both conservative Cys residues. The part of native molecules F_N was calculated on the basis of ellipticity at 222 nm. For comparison the data of iRFP670 apoprotein (gray circles) are shown ($n=3$; error bars are s.e.m.).



Supplementary Figure 8. Brightness of iRFP670, iRFP682 and their mutants in mammalian cells. (a) HeLa cells were co-transfected with one of the iRFP670 variants and EGFP as the transfection efficiency control and analyzed in NIR (x axis: excitation at 635 nm and emission at 710/20 nm) and green (y axis: excitation at 488 nm and emission at 530/30 nm) channels using flow cytometry. (b) The same as in (a) but transfected with the iRFP682 variants. (c) The representative images of HeLa cells transfected with iRFP670 variants (top row) and with iRFP682 variants (bottom row) are shown. The 605/40 nm excitation and 667/30 nm emission filters were used. The exposure time for cells expressing original iRFP670 was 8-fold shorter and for cells expressing original iRFP682 was 5-fold shorter than for all others. Scale bar is 10 μ m. (d) NIR fluorescence of HeLa cells in (a,b) was normalized to that of EGFP intensity and to excitation and emission spectra of each of the iRFP variants. The normalized fluorescence intensities of the cells expressing an iRFP713 control (see Fig. 6) were assumed 100%.

Supplementary Table 1. Midpoints of GdnHCl-induced denaturation of iRFP670, iRFP682, iRFP713 and their variants with different location of Cys residues.

NIR FP group	Localization of Cys capable to bind BV	NIR FP variant	C_m of GdnHCl (M)
I	Cys15 in PAS	iRFP713	2.5 ± 0.1
		iRFP713/T204A	2.6 ± 0.1
		iRFP682/C256S	2.5 ± 0.1
		iRFP670/C256S	2.4 ± 0.1
II	no both Cys	iRFP713/C15S	1.7 ± 0.2
		iRFP682/C15S/C256S	1.8 ± 0.1
		iRFP670/C15S/C256S	2.3 ± 0.1
III	Cys256 in GAF	iRFP713/C15S/V256C	2.3 ± 0.1
		iRFP713/C15S/V256C/T204A	1.8 ± 0.1
		iRFP682/C15S	1.8 ± 0.1
		iRFP670/C15S	2.6 ± 0.1
IV	Cys15 in PAS and Cys256 in GAF	iRFP713/V256C	2.8 ± 0.1
		iRFP682	2.8 ± 0.1
		iRFP670	3.5 ± 0.1
apofoms	no BV	iRFP713	1.8 ± 0.2
		iRFP682/C15S/C256S	1.6 ± 0.1
		iRFP670/C15S/C256S	2.3 ± 0.2

Supplementary References.

Shcherbakova, D. M. & Verkhusha, V. V. Near-infrared fluorescent proteins for multicolor *in vivo* imaging. *Nature Methods* **10**, 751-754 (2013).